Increased central adiposity and decreased subcutaneous adipose tissue 11β‐hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose tolerance—A longitudinal cohort study

Crowley, R; Woods, C; Hughes, B; Gray, J; McCarthy, T; Taylor, A; Gathercole, L; Shackleton, C; Crabtree, N; Arlt, W; Stewart, P; Tomlinson, J

Journal article

Increased central adiposity and decreased subcutaneous adipose tissue 11β‐hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose tolerance—A longitudinal cohort study

Abstract:: Objective and Context Increasing adiposity, ageing and tissue‐specific regeneration of cortisol through the activity of 11β‐hydroxysteroid dehydrogenase type 1 have been associated with deterioration in glucose tolerance. We undertook a longitudinal, prospective clinical study to determine if alterations in local glucocorticoid metabolism track with changes in glucose tolerance.

Design, Patients, and Measurements Sixty‐five overweight/obese individuals (mean age 50.3 ± 7.3 years) underwent oral glucose tolerance testing, body composition assessment, subcutaneous adipose tissue biopsy and urinary steroid metabolite analysis annually for up to 5 years. Participants were categorized into those in whom glucose tolerance deteriorated (“deteriorators”) or improved (“improvers”).

Results Deteriorating glucose tolerance was associated with increasing total and trunk fat mass and increased subcutaneous adipose tissue expression of lipogenic genes. Subcutaneous adipose tissue 11β‐HSD1 gene expression decreased in deteriorators, and at study completion, it was highest in the improvers. There was a significant negative correlation between change in area under the curve glucose and 11β‐HSD1 expression. Global 11β‐HSD1 activity did not change and was not different between deteriorators and improvers at baseline or follow‐up.

Conclusion Longitudinal deterioration in metabolic phenotype is not associated with increased 11β‐HSD1 activity, but decreased subcutaneous adipose tissue gene expression. These changes may represent a compensatory mechanism to decrease local glucocorticoid exposure in the face of an adverse metabolic phenotype.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Crowley, R., Woods, C., Hughes, B., Gray, J., McCarthy, T., Taylor, A., Gathercole, L., Shackleton, C., Crabtree, N., Arlt, W., Stewart, P., & Tomlinson, J. (2019). Increased central adiposity and decreased subcutaneous adipose tissue 11β‐hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose tolerance—A longitudinal cohort study. Clinical Endocrinology, 91(1), 72–81.

MLA Style

Crowley, R., et al. “Increased Central Adiposity and Decreased Subcutaneous Adipose Tissue 11β‐Hydroxysteroid Dehydrogenase Type 1 Are Associated with Deterioration in Glucose Tolerance—A Longitudinal Cohort Study.” Clinical Endocrinology, vol. 91, no. 1, Wiley, 2019, pp. 72–81.

Chicago Style

Crowley, R, C Woods, B Hughes, J Gray, T McCarthy, A Taylor, L Gathercole, et al. 2019. “Increased Central Adiposity and Decreased Subcutaneous Adipose Tissue 11β‐Hydroxysteroid Dehydrogenase Type 1 Are Associated with Deterioration in Glucose Tolerance—A Longitudinal Cohort Study.” Clinical Endocrinology 91 (1): 72–81.
Share
Print